



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/639,949	08/12/2003	Rajat Sethi	12695.6USD5	6992
23552	7590 04/10/2006		EXAM	INER
MERCHANT & GOULD PC			JONES, DWAYNE C	
P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 04/10/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Commons	10/639,949	SETHI ET AL.				
Office Action Summary	Examiner	Art Unit				
	Dwayne C. Jones	1614				
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet w	vith the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by stat Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNI 1.136(a). In no event, however, may a od will apply and will expire SIX (6) MO ute, cause the application to become A	reply be timely filed  NTHS from the mailing date of this communication.  BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on the	e response of 23MAR2006.					
,— · · · · · · · · · · · · · · · · · · ·	nis action is non-final.					
.—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	•	•				
Disposition of Claims						
4) Claim(s) 1-6 is/are pending in the application	٦.	•				
4a) Of the above claim(s) is/are withdo	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-6</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and	l/or election requirement.					
Application Papers						
9) The specification is objected to by the Exami	ner.					
10) The drawing(s) filed on is/are: a) a		by the Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the corre	ection is required if the drawing	g(s) is objected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the	Examiner. Note the attache	ed Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreignal ☐ All b) ☐ Some * c) ☐ None of:		§ 119(a)-(d) or (f).				
1. Certified copies of the priority docume						
2. Certified copies of the priority docume						
3. Copies of the certified copies of the pr	•	n received in this National Stage				
application from the International Bure	`	t received				
* See the attached detailed Office action for a li	st of the certified copies no	received.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview	Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No	(s)/Mail Date				
<ol> <li>Information Disclosure Statement(s) (PTO-1449 or PTO/SB/0 Paper No(s)/Mail Date <u>3/23/6</u>.</li> </ol>	5) Notice of 6) Other:	Informal Patent Application (PTO-152)				

Application/Control Number: 10/639,949

Art Unit: 1614

#### **DETAILED ACTION**

#### Status of Claims

- 1. Claims 1-6 are pending.
- 2. Claims 1-6 are rejected.

## Response to Arguments

3. Applicant's arguments with respect to claims 1-6 have been considered but are most in view of the new ground(s) of rejection.

## Information Disclosure Statement

4. The information disclosure statement of March 23, 2006 (1 sheet) has been reviewed and considered, see enclosed copy of PTO FORM 1449.

## **Double Patenting**

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

6. Claims 1-6 rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 12-34 of U.S. Patent No. 6,890,943. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instantly claimed subject matter as well as the prior art reference of U.S. Patent No. 6,890,943 teach of the administration of the pyridoxal analogue compounds, as set forth in claim 12 of U.S. Patent No. 6,890,943, along with the concurrent administration of a therapeutic cardiovascular compound selected form the group consisting of a calcium channel blocker, an anti-thrombotic agent, a β-adrenergic receptor antagonist for the treatment of cardiovascular and related diseases, which is defined in the specification of U.S. Patent No. 6,890,943 as embracing the

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (571) 272-0578. The examiner can normally be reached on Mondays, Tuesdays, Wednesdays, and Fridays from 8:30 am to 6:00 pm.

condition of blood coagulation diseases, (see claim 26).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, may be reached at (571) 272-0951. The official fax No. for correspondence is (571)-273-8300.

Also, please note that U.S. patents and U.S. patent application publications are no longer supplied with Office actions. Accordingly, the <u>cited U.S.</u> patents and patent application publications are available for download via the Office's PAIR, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. As an alternate source, <u>all U.S.</u> patents and patent application

**Art Unit: 1614** 

publications are available on the USPTO web site (<u>www.uspto.gov</u>), from the Office of Public Records and from commercial sources.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a> Should you have any questions on access to the Private PAIR system, contact the Electronic Pusiness Center (EBC) at 1-866-217-9197 (toll free).

DWAYNEJONES PRIMARY EXAMINER

Tech Ctr. 1614 April 4, 2006